The Technical Analyst
Virios Therapeutics, LLC [VIRI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Virios Therapeutics, LLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.65% $0.470
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.04 mill |
| EPS: | -0.280 |
| P/E: | -1.680 |
| Earnings Date: | Mar 18, 2024 |
| SharesOutstanding: | 19.26 mill |
| Avg Daily Volume: | 0.304 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.680 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.29x |
| Company: PE -1.680 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.177 (-62.37%) $-0.293 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.394 - 0.546 ( +/- 16.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-26 | Pridgen William | Buy | 2 917 | Stock Option (right to buy) |
| 2024-02-26 | Thomas John C | Buy | 4 167 | Stock Option (right to buy) |
| 2024-02-26 | Whitley Richard James | Buy | 4 000 | Stock Option (right to buy) |
| 2024-02-26 | Keefer David R | Buy | 4 709 | Stock Option (right to buy) |
| 2024-02-26 | Burch Richard Alan | Buy | 2 917 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 99.86 |
| Last 92 transactions |
| Buy: 2 833 595 | Sell: 299 106 |
Forecast:
16:00 - $0.470
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.470
Forecast 2: 16:00 - $0.470
Forecast 3: 16:00 - $0.470
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.470 (1.65% ) |
| Volume | 0.0383 mill |
| Avg. Vol. | 0.304 mill |
| % of Avg. Vol | 12.60 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VIRI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VIRI
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Latest Press Releases
2024-03-26 09:15:00 - Press Release
Virios Therapeutics Announces Publication Of International Patent For Imc-2 Covering Antiviral Treatment Of Long-covid
- new patent would extend coverage and expand potential value of virios' antiviral pipeline globally – - active long-covid characterized by immune dysfunction leading to recurrent herpesviruses reactivation - - published data indicates increased epstein-barr herpes virus in long-covid patients, highlighting potential for antiviral therapy to treat fatigue and other long-covid symptoms – atlanta, march 26, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today announced that the world intellectual property organization (wipo) has published virios' global patent application titled “valacyclovir and celecoxib for the treatment of alzheimer's and covid-19”, which covers the use of imc-2, a proprietary combination of valacyclovir and celecoxib...
2024-02-29 09:15:00 - Press Release
Virios Therapeutics Announces fourth Quarter And Full Year 2023 Financial Results
Atlanta, feb. 29, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today announced financial results for the fourth quarter and full year ended december 31, 2023.
2024-02-28 09:15:00 - Press Release
Virios Therapeutics Issues Shareholder Letter Highlighting corporate Progress And Key Upcoming Milestones
Atlanta, ga., feb. 28, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today issued a shareholder letter highlighting the company's progress and key milestones in 2024.
2024-01-22 09:00:00 - Press Release
Virios Therapeutics Announces Plans To Advance Development of Imc-2 As Treatment For Symptoms Associated With Long-covid
- placebo-controlled clinical proof of concept data expected in mid-2024 - - targeting initiation of imc-2 phase 2 program in 2h 2024 -
2024-01-02 07:05:00 - Press Release
Virios Therapeutics, Inc. Reaches Alignment With Fda On Requirements For Advancing Development Candidate Imc-2 As Treatment For Long-covid
Atlanta, jan. 02, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today announced receipt of the food and drug administration's (“fda”) feedback on requirements for advancing imc-2 (combination of valacyclovir + celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with lc illness, also known as post-acute sequelae of sars-cov-2 infection (“pasc”).
Latest News
2023-11-13 11:21:04 - Seeking Alpha
Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Duncan - CEO Angela Walsh - SVP, Finance & Treasurer Mike Gendreau - CMO Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update.
2023-11-06 07:05:00 - GlobeNewsWire
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November 13, 2023 at 8:30 a.m. ET to discuss the results and provide a corporate update.
2023-10-12 07:05:00 - GlobeNewsWire
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.
2023-09-12 07:05:00 - GlobeNewsWire
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.
2023-08-10 10:05:09 - Seeking Alpha
Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Angela Walsh - Senior Vice President, Finance & Treasurer Greg Duncan - Chief Executive Officer Mike Gendreau - Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Q2 2023 Earnings Update.
2023-05-11 07:49:18 - InvestorPlace
VIRI Stock Earnings: Virios Beats EPS Estimates
Virios Therapeutics (NASDAQ: VIRI ) reported first quarter results for 2023. Virios reported a loss per share of 8 cents.
2023-05-04 07:05:00 - GlobeNewsWire
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.
2023-04-25 11:30:12 - MarketBeat
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020.
2023-04-25 10:48:02 - Proactive Investors
Virios Therapeutics stock doubles as fibromyalgia program moves forward
Virios Therapeutics shares more than doubled after the biotechnology company announced that its proposed Phase 3 program featuring its lead development candidate IMC-1 for fibromyalgia has been considered acceptable based on initial feedback from the US Food and Drug Administration (FDA). IMC-1 is a novel, fixed-dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the company's end goal being the reduction of virally promoted fibromyalgia disease symptoms.
2023-04-25 08:01:15 - InvestorPlace
Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?
Virios Therapeutics (NASDAQ: VIRI ) stock is rocketing higher on Tuesday following an update on its planned Phase 3 clinical trial of IMC-1. IMC-1 is Virios Therapeutics' lead drug candidate in development for the treatment of herpes virus replication.